An analyst at Cantor Fitzgerald found concerning data about potential side effects of Amgen’s obesity drug MariTide, causing a $12 billion loss in market value. Despite Amgen denying a link between the drug and bone density loss, concerns remain. FDA Commissioner Robert Califf expresses uncertainty about the agency’s future under the incoming Trump administration, highlighting potential challenges in hiring skilled employees. Political pressure has always influenced FDA decisions, and Califf acknowledges the possibility of overruling by higher authorities. Overall, Amgen faces uncertainties about its drug’s safety, while the FDA braces for potential changes under a new leadership.
Source link
We’re reading about Amgen data controversy, J&J suing the feds
